Moderna, Inc. (NASDAQ: MRNA) had its "market perform" rating re-affirmed by analysts at William Blair.
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Morgan Stanley from $39.00 to $32.00. They now have an "equal weight" rating on the stock.
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025 [Yahoo! Finance]
Moderna, Inc. (MRNA): Among Stocks To Trade Without Tariffs And Interest Rate Fears [Yahoo! Finance]
Moderna, biotech stocks slide following resignation of FDA official Peter Marks [Yahoo! Finance Canada]